Abstract: The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.
Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
Type:
Grant
Filed:
January 21, 2020
Date of Patent:
October 31, 2023
Assignee:
Celera Corporation
Inventors:
Steve Ruben, Tao He, Candy Lee, Karen Van Orden, Paul Moore
Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.
Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
October 24, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.
Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
Type:
Grant
Filed:
June 7, 2017
Date of Patent:
October 17, 2023
Assignee:
PRECIGEN, INC.
Inventors:
Rutul Shah, Tim Chan, Peter Emtage, Ramya Yarlagadda
Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Type:
Grant
Filed:
September 20, 2017
Date of Patent:
October 17, 2023
Assignees:
BioNTech SE, ASTELLAS PHARMA INC.
Inventors:
Ugur Sahin, Christiane Stadler, Leyla Fischer, Arne Jendretzki, Özlem Türeci, Fabrice Le Gall, Maria Kreuzberg
Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
Type:
Grant
Filed:
June 8, 2018
Date of Patent:
October 10, 2023
Assignee:
BLACK BELT THERAPEUTICS LIMITED
Inventors:
Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
Abstract: The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same.
Type:
Grant
Filed:
April 13, 2021
Date of Patent:
October 10, 2023
Assignee:
ALLIGATOR BIOSCIENCE AB
Inventors:
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
Abstract: The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients' blood, including nucleosome-bound cfDNA, exosome-bound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases.
Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
October 3, 2023
Assignee:
Surrozen Operating, Inc.
Inventors:
Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Claudia Yvonne Janda, Tristan William Fowler, Helene Baribault, Kuo-Pao Lai, Liqin Xie, Randall J. Brezski, Chenggang Lu
Abstract: The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients' blood, including nucleosome-bound cfDNA, exosome-bound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases.
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
Type:
Grant
Filed:
December 9, 2022
Date of Patent:
September 19, 2023
Assignee:
Dyne Therapeutics, Inc.
Inventors:
Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
Type:
Grant
Filed:
August 10, 2020
Date of Patent:
September 12, 2023
Assignee:
Anji Bruno, LLC
Inventors:
Luke Evnin, Jeanmarie Dean Guenot, Lori Kunkel
Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
Type:
Grant
Filed:
May 21, 2019
Date of Patent:
September 5, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
Abstract: The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.
Abstract: The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
Abstract: The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.
Abstract: Provided herein are immunomodulatory proteins comprising variant PD-L2 and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
Type:
Grant
Filed:
March 13, 2018
Date of Patent:
August 22, 2023
Assignee:
Alpine Immune Sciences, Inc.
Inventors:
Ryan Swanson, Michael Kornacker, Mark F. Maurer, Dan Ardourel, Daniel William Demonte, Joseph L. Kuijper